Ingestion of which of the following drug during pregnancy increase the risk of vaginal adenocarcinoma in a female offspring?
**Core Concept**
The question requires knowledge of a specific teratogenic effect of a drug during pregnancy. The underlying principle is that certain drugs can increase the risk of specific congenital anomalies or cancers in the offspring.
**Why the Correct Answer is Right**
The correct answer is diethylstilbestrol (DES), a synthetic estrogen that was previously used to prevent miscarriages and other pregnancy complications. However, it has been linked to an increased risk of vaginal adenocarcinoma in female offspring exposed in utero. DES acts as an estrogen agonist, which can disrupt normal fetal development and increase the risk of certain cancers.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not specified, so we cannot evaluate it. However, if it were a different drug, it would not be correct.
* **Option B:** This option is also not specified, so we cannot evaluate it. However, if it were a different drug, it would not be correct.
* **Option C:** This option is not specified, so we cannot evaluate it. However, if it were a different drug, it would not be correct.
**Clinical Pearl / High-Yield Fact**
Diethylstilbestrol (DES) was banned in the 1970s due to its association with vaginal adenocarcinoma in female offspring. Healthcare providers should be aware of this teratogenic effect and counsel patients about the risks of DES exposure during pregnancy.
**Correct Answer:** D. Diethylstilbestrol (DES).